In 2020, avapritinib was approved as a first-line treatment for GIST tumors with confirmed PDGFRA D842V mutation GIST, a subtype of GIST that is generally resistant to standard GIST treatment regimens. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.